VistaGen Therapeutics, Inc. (VTGN)

NASDAQ: VTGN · IEX Real-Time Price · USD
5.28
+0.71 (15.54%)
At close: Mar 28, 2024, 4:00 PM
5.55
+0.27 (5.11%)
After-hours: Mar 28, 2024, 7:59 PM EDT
15.54%
Market Cap 140.80M
Revenue (ttm) 1.04M
Net Income (ttm) -32.07M
Shares Out 27.03M
EPS (ttm) -3.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,233,119
Open 4.59
Previous Close 4.57
Day's Range 4.59 - 5.67
52-Week Range 1.62 - 24.71
Beta 0.78
Analysts Strong Buy
Price Target 19.00 (+259.85%)
Earnings Date Feb 13, 2024

About VTGN

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 37
Stock Exchange NASDAQ
Ticker Symbol VTGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for VTGN stock is "Strong Buy." The 12-month stock price forecast is $19.0, which is an increase of 259.85% from the latest price.

Price Target
$19.0
(259.85% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

This overlooked corner of women's health could be a $350 billion market opportunity

Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.

Other symbols: PFEPGNYBTMDDARE
13 days ago - CNBC

Vistagen to Present at Stifel 2024 Virtual CNS Days

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals a...

18 days ago - Business Wire

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals a...

4 weeks ago - Business Wire

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapi...

6 weeks ago - Business Wire

Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapi...

7 weeks ago - Business Wire

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #CNSdisorders--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

3 months ago - Business Wire

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

5 months ago - Business Wire

Vistagen to Present at Stifel 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

5 months ago - Business Wire

Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

5 months ago - Business Wire

Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, ...

5 months ago - Business Wire

Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

6 months ago - Business Wire

Vistagen Announces Pricing of $100 Million Underwritten Offering

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the t...

6 months ago - Business Wire

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

7 months ago - Business Wire

Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen's Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan

SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)---- $VTGN #menopause--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

7 months ago - Business Wire

Vistagen Appoints Cindy Anderson as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individual...

7 months ago - Business Wire

Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

8 months ago - Business Wire

Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

8 months ago - Business Wire

Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals li...

8 months ago - Business Wire

Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray's Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individual...

9 months ago - Business Wire

Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson's Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

9 months ago - Business Wire

Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results.

9 months ago - Business Wire

Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

9 months ago - Business Wire

Vistagen Regains Full Compliance with Nasdaq Listing Requirements

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua...

10 months ago - Business Wire

Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individual...

10 months ago - Business Wire

Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BBLGFRESYTEN
10 months ago - Benzinga